Searching for your content...
Phone
877-269-7890 from 8 AM - 10 PM ET
Contact Cision
Submission supported by positive results of a Phase III study showing immune response and tolerability in adults aged 50-59 Adults aged 50 and above with underlying medical conditions are at...
Only 9% Canadians aged 50 and older fully understand the incidence of developing shingles, with 72% greatly underestimating or declaring not knowing their risk of developing the disease 1 in 2 (49%)...
Health Canada's acceptance of the submission follows that of the Ministry of Health, Labour and Welfare (WHLW) in Japan and approval by the US Food and Drug Administration (FDA) and the European...
Jemperli is the only immuno-oncology treatment approved for this patient population in combination with chemotherapy in Canada. An estimated 20-29% of all endometrial cancers are dMMR/MSI-H and...
The $2 million contribution will support the investigation into evidence-based solutions to improve Canadians' lung health. MISSISSAUGA, ON, Sept. 26, 2023 /CNW/ - GSK is investing $2 million in...
Canadians aged 60 years and older can now better protect themselves against RSV disease Approval of Arexvy was based on a comprehensive Phase III clinical trial program that showed high vaccine...
Grant recognizes CCfV's national leadership and Nova Scotian contribution to Canada's research capabilities, expected to attract top talent. MISSISSAUGA, ON, May 31, 2023 /CNW/ - GSK announces a $1...
The new chair will aim to close gaps in vaccine education for students and practicing healthcare professionals, with a focus on pharmacists MISSISSAUGA, ON, May 5, 2023 /CNW/ - The University of...
New investment in long-standing partnership will help create jobs and attract top talent in burgeoning biotech industry, says founding chair. MISSISSAUGA, ON, Feb. 8, 2023 /CNW/ - Biopharma company...
Vaccine candidate has the potential to be the first available to help protect adults aged 60 years and older from lower respiratory tract disease caused by respiratory syncytial virus Application...
The 2022-2026 contract continues a 20 year-long relationship with the Government of Canada for pandemic and seasonal influenza vaccines Up to 80 million doses of pandemic influenza vaccine to be...
Canadian regulatory submission acceptance follows that of the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) as well as the approval of Duvroq in Japan. MISSISSAUGA, ON,...
GSK Canada's new office will remain in Mississauga, where the company has been headquartered for over 30 years Performance with Choice—GSK's approach to hybrid working—provides employees the...
MISSISSAUGA, ON, Jan. 6, 2022 /CNW/ - GSK today announced it has signed agreements with the Government of Canada to supply 20,000 doses of Sotrovimab for injection. Sotrovimab is a COVID-19...
MISSISSAUGA, ON, Dec. 23, 2021 /CNW/ - GSK announces today that it has been granted Notice of Compliance with conditions for its endometrial cancer treatment JEMPERLI (dostarlimab for injection) by...
MISSISSAUGA, ON, Nov. 25, 2021 /CNW/ - GlaxoSmithKline Inc. today announced that SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) has been approved in Canada for the prevention of shingles (herpes...
MISSISSAUGA, ON, Nov. 12, 2021 /CNW/ - GSK has been recognized as one of Canada's Top 100 Employers for 2022, marking the third consecutive year the company has earned this prestigious honour....
MISSISSAUGA, ON, Nov. 8, 2021 /CNW/ - NUCALA (mepolizumab) is now approved in Canada as an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic...
Rions en action avec Lise Dion presented by Voltaren™ is an interactive comedy experience bringing people together through laughter and movement on a series of walks in Montreal taking place on...
MISSISSAUGA, ON, Oct. 4, 2021 /CNW/ - GSK today announced it has signed an agreement with the Government of Canada to supply 10,000 doses of Sotrovimab for injection, a COVID-19 monoclonal antibody...
3 in 4 people (including 81% women) now regard personal health and wellbeing as very important, up from 2 in 3 before COVID. Global survey shows Canadian adults over age 50 perceive good health as...
MISSISSAUGA, ON, Sept. 15, 2021 /CNW/ - NUCALA (mepolizumab) is now approved in Canada as an add-on to standard therapy for the treatment of adults with hypereosinophilic syndrome (HES) for ≥6 months ...
MISSISSAUGA, ON, July 30, 2021 /CNW/ - GSK announced today that Health Canada has granted an Interim Order authorization for Sotrovimab for Injection (sotrovimab, previously VIR-7831) for the...
MISSISSAUGA, ON, July 30, 2021 /CNW/ - BENLYSTA (belimumab) has been approved in Canada for the treatment of active lupus nephritis (LN) in adult patients.[i] BENLYSTA is available as an intravenous...
MISSISSAUGA, ON, May 4, 2021 /CNW/ - ZEJULA (niraparib) has received conditional positive recommendations for reimbursement from the Canadian Agency of Drugs and Technology in Health (CADTH) and...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.